As a global healthcare company with a century-long commitment to furthering the advancements in diabetes care, Novo Nordisk is taking another critical stride to expand its manufacturing prowess. The Danish multinational pharmaceutical manufacturer recently announced plans to establish a whopping $4.1 billion production facility in